Pulmonary pharmacology & therapeutics
-
Pulm Pharmacol Ther · Jun 2018
Effects of fluticasone propionate and budesonide on the expression of immune defense genes in bronchial epithelial cells.
COPD patients have increased risk of pneumonia when treated with fluticasone propionate (FP), whereas this is generally not the case with budesonide (BUD) treatment. We hypothesized that BUD and FP differentially affect the expression of immune defense genes. ⋯ Treatment of human bronchial epithelial cells with BUD results in significantly higher expression of specific immune defense genes than treatment with FP. The differential regulation of these immune defense genes may help to explain the clinical observation that BUD and FP treatment differ with respect to the risk of developing pneumonia in COPD.